Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
XBH-25 by GV20 Therapeutics for Solid Tumor: Likelihood of Approval
XBH-25 is under clinical development by GV20 Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
XBH-25 by GV20 Therapeutics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
XBH-25 is under clinical development by GV20 Therapeutics and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...
XBH-25 by GV20 Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
XBH-25 is under clinical development by GV20 Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma...
XBH-25 by GV20 Therapeutics for Bladder Carcinoma: Likelihood of Approval
XBH-25 is under clinical development by GV20 Therapeutics and currently in Phase I for Bladder Carcinoma. According to GlobalData, Phase...
XBH-25 by GV20 Therapeutics for Adenocarcinoma: Likelihood of Approval
XBH-25 is under clinical development by GV20 Therapeutics and currently in Phase I for Adenocarcinoma. According to GlobalData, Phase I...
XBH-25 by GV20 Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
XBH-25 is under clinical development by GV20 Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...
XBH-25 by GV20 Therapeutics for Endometrial Cancer: Likelihood of Approval
XBH-25 is under clinical development by GV20 Therapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
XBH-25 by GV20 Therapeutics for Melanoma: Likelihood of Approval
XBH-25 is under clinical development by GV20 Therapeutics and currently in Phase I for Melanoma. According to GlobalData, Phase I...